Jan- Feb 2020:
..’Two recent studies from China [3,4] have asked, can mesenchymal stem cells (MSC) treat COVID-19 pneumonia, based on known immunomodulatory and reparative properties of stem cells?
Both studies reveal remarkable reversal of symptoms even in severe-critical conditions. ...’

...’ The second study [4] was a pilot clinical trial to assess whether MSC transplantation could Considering needs for mitigation of the current COVID-19 pandemic, with priority to keep mortality as low as possible, the finding that MSC are safe and can reverse severe critical disease with high potency is a major breakthrough representing an entirely new biological approach to treatment that needs to be developed urgently.
To this end, stem cell biotech companies are joining forces (e.g., Athersys and Mesoblast) [8],whilst the nanotechnologybased synthetic stem cell LIFNano is ready for cGMP production at scale today [7]. ...’

... RAS inhibitors, ACEI and AT1R, may be potential therapeutic tools for COVID-19.

Additionally, intravenous transplantation of ACE2-mesenchymal stem cells (MSCs), blocking of FcR with immunoglobulin (IVIG), and systemic anti-inflammatory drugs to reduce cytokine storm are also potential therapeutic strategies for severe COVID-19 [61,79].

Thankyou for posting this . ( maybe we are related )

Very important reading .